Evidence map›Paper›PMID 32023822›Full record

ArticleInternational journal of molecular sciences2020

Gastric Corpus Mucosal Hyperplasia and Neuroendocrine Cell Hyperplasia, but not Spasmolytic Polypeptide-Expressing Metaplasia, Is Prevented by a Gastrin Receptor Antagonist in H

Kristin Matre Aasarød, Helge Lyder Waldum, Astrid Kamilla Stunes, Arne Kristian Sandvik, Arnar Flatberg, Patricia Mjønes, Unni Syversen, Ingunn Bakke, Reidar Fossmark

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Kristin Matre AasarødDepartment of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, NTNU-Norwegian University of Science and Technology, 7491 Trondheim, Norway.
Helge Lyder WaldumDepartment of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, NTNU-Norwegian University of Science and Technology, 7491 Trondheim, Norway.ORCID 0000-0002-3137-0843
Astrid Kamilla StunesDepartment of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, NTNU-Norwegian University of Science and Technology, 7491 Trondheim, Norway.
Arne Kristian SandvikDepartment of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, NTNU-Norwegian University of Science and Technology, 7491 Trondheim, Norway.
Arnar FlatbergDepartment of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, NTNU-Norwegian University of Science and Technology, 7491 Trondheim, Norway.
Patricia MjønesDepartment of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, NTNU-Norwegian University of Science and Technology, 7491 Trondheim, Norway.ORCID 0000-0001-7678-994X
Unni SyversenDepartment of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, NTNU-Norwegian University of Science and Technology, 7491 Trondheim, Norway.
Ingunn BakkeDepartment of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, NTNU-Norwegian University of Science and Technology, 7491 Trondheim, Norway.
Reidar FossmarkDepartment of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, NTNU-Norwegian University of Science and Technology, 7491 Trondheim, Norway.ORCID 0000-0002-5365-9357
Norwegian University of Science and Technology · NO

Funding

Norges Teknisk-Naturvitenskapelige Universitet noneNowegian Gastroenterologists Association none
6 · The paper itself

Abstract

Proton pump inhibitor use is associated with an increased risk of gastric cancer, which may be mediated by hypergastrinemia. Spasmolytic polypeptide-expression metaplasia (SPEM) has been proposed as a precursor of gastric cancer. We have examined the effects of the gastrin receptor antagonist netazepide (NTZ) or vehicle on the gastric corpus mucosa of H

Indexed as

AnimalsBenzodiazepinonesExome SequencingFemaleGastric MucosaGene Expression ProfilingGene Expression RegulationH(+)-K(+)-Exchanging ATPaseHumansHyperplasiaInjections, SubcutaneousIn Situ HybridizationIntercellular Signaling Peptides and ProteinsMaleMetaplasiaMiceBenzodiazepinonesH(+)-K(+)-Exchanging ATPaseIntercellular Signaling Peptides and ProteinsPhenylurea Compoundsspasmolytic polypeptideYF 476acid inhibitiongastrinnetazepideneuroendocrine cellsSPEM

Identifiers

PMID32023822
PMCPMC7037105
OpenAlexW3003219124

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.